Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYi L. HwaDDDavid Dingli

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improved progression-free survival in relapsed multiple myeloma, suggesting an all-oral regimen may be effective.

Key Points

  • To evaluate the efficacy and safety of selinexor combined with pomalidomide and dexamethasone in relapsed multiple myeloma.
  • Single arm, phase 2 study design
  • Patients received selinexor, pomalidomide, and dexamethasone in 28-day cycles
  • Primary endpoints included overall response rate, progression-free survival, and safety assessment
  • Overall response rate was 61%
  • Median progression-free survival was 24 months
  • Safety profile indicated manageable toxicities with no grade 5 events

Cite This Study

Hwa et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df58https://doi.org/10.1182/blood-2025-2281
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma2024 · 10 citations
  2. 2Renal response of selinexor,  bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study2025
  3. 3Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  4. 4Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study2024 · 14 citations
  5. 5Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study2026